Ascentage Pharma’s US Shares Climb

Ascentage Pharma raises $126m in first biotech IPO of 2025
The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood cancer.
Ascentage Pharma’s US Shares Climb After $126 Million IPO
Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s US trading debut, after pricing its $126.4 million initial public offering at a discount to its Asian stock.
Ascentage Pharma CEO Dr. Yang on IPO
Dr. Dajun Yang, Ascentage Pharma CEO, joins 'Closing Bell Overtime' to talk today's IPO. Marilyn Manson won’t face sexual assault, domestic violence charges in LA
Rockville's Ascentage Pharma seeks to raise $134M in U.S. IPO
A global biopharma with a U.S. headquarters in Montgomery County is gearing up to go public on a U.S. exchange.
Ascentage prices first biotech IPO of 2025, raising $126M
The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.
Ascentage Pharma IPO opens flat
IPO began trading Friday on the NASDAQ. Shares opened at $17.25 per ADS, in line with the initial public offering (IPO) price of $17.25. The pharmaceutical company, already listed on the Main Board of the Stock Exchange of Hong Kong Limited under the code 6855.
Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut
The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics
Ascentage Pharma raises $126M via U.S. IPO (update)
Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.
Chinese Biotech Ascentage Aims For $134M IPO
Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia and for certain types of chronic myeloid leukemia.
Ascentage Pharma sets terms for $149 million US IPO
Suzhou, China-based Ascentage Pharma revealed that it plans to raise $149 million by offering 7.3 million American Depositary Shares (ADSs) at $20.34, the as-converted January 17 close of its shares on the Hong Kong Stock Exchange.
Takeda-backed Ascentage Pharma aims to raise $126 million in US IPO
Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.
U.S. IPO Weekly Recap: Venture Global Prices A Pared-Down IPO As More Sizable Deals Join The Pipeline
Seven IPOs and one SPAC priced this past week, as more sizable issuers filed to go public in the US. Read more here.
Ascentage Pharma ADSs to Begin Trading on Nasdaq
Ascentage Pharma Group said its American depositary shares were slated to begin trading on the Nasdaq Global Market on Friday, with its initial public offering priced at $17.25 per ADS.